Array BioPharma reports 18.

Array will continue to advance MEK162 into an expansion stage of a Phase 1 trial at the maximum tolerated dose in biliary tract cancers patients at ten scientific sites in North America. The expansion study is designed to evaluate safety, pharmacodynamics and pharmacokinetics of MEK162 in patients with biliary tract malignancy. Related StoriesOvarian cancer sufferers with a history of oral contraceptive use have got better outcomesFDA grants accelerated acceptance for Tagrisso to treat individuals with advanced NSCLCSausages With Antioxidants From Berries To Prevent CancerPartnerships advance with Amgen, Genentech, Celgene and InterMune: Amgen collaboration AMG 151 / ARRY-403 – GK activator for type 2 diabetes: Array continuing a Phase 1 multiple ascending dose clinical trial in individuals with type 2 diabetes, with AMG 151 / ARRY-403, a small-molecule glucokinase activator that Array partnered with Amgen Inc.Related StoriesResilience-based programs might help LGBT youths deal with detrimental stressorsGlan Clwyd Medical center N Wales spend money on Esaote's G-Scan MRI device for weight-bearing scanningBoston Kids's and Rock Health synergy to accelerate advancement of pediatric wellness technologiesMany doctors dread that openly addressing the problem of suicide in depressed individuals may result in suicidal thoughts or actions, Schulberg says. With old patients, doctors should open up discussions by addressing end-of-life issues.